Journals / Maltepe Tıp Dergisi / 2017 / Cilt: 9 - Sayı: 2

Connective tissue diseases and liver

Bağ dokusu hastalıkları ve karaciğer

Pages
38–41
Publication Date
2017-08-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Though it is not always possible to distinguish this triple interaction from one another, it is an important factor that should be considered in terms of the success of the treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The liver is an organ that is affected by both metabolic and inflammatory events in general physiognomy.
📊
Key Findings & Data:Therefore, it is unthinkable not to be affected by connective tissue diseases.
💡
Conclusion & Impact:Though it is not always possible to distinguish this triple interaction from one another, it is an important factor that should be considered in terms of the success of the treatment.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:bağ dokusu hastalıkları · karaciğer · connective tissue diseases

Abstract

The liver is an organ that is affected by both metabolic and inflammatory events in general physiognomy. Therefore, it is unthinkable not to be affected by connective tissue diseases. However, this interaction is often overlooked. This interaction can be summarized as: liver involvement due to systemic connective tissue diseases, autoimmune liver diseases and effects on the liver of drugs used in these diseases. Though it is not always possible to distinguish this triple interaction from one another, it is an important factor that should be considered in terms of the success of the treatment.

Özet

Karaciğer genel fizyonomi içerisinde hem metabolik hem de inflamatuvar olaylardan etkilenen bir organdır. Dolayısıyla, bağ dokusu hastalıklarından etkilenmemesi düşünülemez. Ancak, bu etkileşim çoğu zaman göz ardı edilmektedir. Bu etkileşim: Sistemik bağ dokusu hastalıklarına bağlı karaciğerin etkilenmesi, otoimmün karaciğer hastalıkları ve bu hastalıklarda kullanılan ilaçların karaciğer üzerindeki etkileri şeklinde özetlenebilir. Her zaman bu üçlü etkileşimi bir birinden ayırt etmek mümkün olmasa da tedavinin başarısı açısından dikkat edilmesi gereken önemli bir faktördür.

🔖

Cite This Article

KAYA, F. Ö., SEZGİN, G., NALBANT, S. (2017). Connective tissue diseases and liver. Maltepe Tıp Dergisi, Cilt: 9 - Sayı: 2, 38–41. https://ajindex.com/articles/230988

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Carlo Selmi, Maria De Santis and M Eric Gershwin. Liver involvement in subjects with rheumatic disease. Selmi et al. Arthritis Research & Therapy 2011, 13:226
  2. Katarina Sedej, Nataša Toplak, Marina Praprotnik, Bo štjan Luzar, Jernej Brecelj and Tadej Avčin. Autoimmune hepatitis as a presenting manifestation of mixed connective tissue disease in a child Case report and review of the literature. Sedej et al. Pediatric Rheumatology (2015) 13:47
  3. Ortega-Hernandez OD, Shoenfeld Y. Mixed connective tissue disease: an overview of clinical manifestations, diagnosis and treatment. Best Pract Res Clin Rheumatol. 2012;26:61–72
  4. Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193–213
  5. Teufel A, Weinmann A, Kahaly GJ, Centner C, Piendl A, Wörns M, et al. Concurrent autoimmune diseases in patients with autoimmune hepatitis. J Clin Gastroenterol. 2010;44:208–213
  6. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–938
  7. Abraham S, Begum S, Isenberg D. Hepatic manifestations of autoimmune rheumatic diseases. Ann Rheum Dis. 2004;63:123–129
  8. Selmi C, De Santis M, Gershwin ME. Liver involvement in subjects with rheumatic disease. Arthritis Res Ther. 2011;13:226
  9. Soultati A, Dourakis S. Hepatic manifestations of autoimmune rheumatic diseases. Ann Gastroenterol. 2005;18:309–324
  10. Min JK, Han NI, Kim JA, Lee YS, Cho CS, Kim HY. A case of cholestatic autoimmune hepatitis and acute liver failure: an unusual hepatic manifestation of mixed connective tissue disease and Sjögren’s syndrome. J Korean Med Sci. 2001;16:512–515
  11. Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors.Garcia Rodriguez et al. Arch Intern Med 1994;154:311
  12. Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis C: a case series.Riley et al Am J Gastroenterol 1998;93:1563-1565 13. Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions.Banks et al. Hepatology 1995;22:820-827
  13. Baun J, Rau R. An update on methotrexate. Curr Opin Rheumatol, 2009; 21: 216-223
  14. Hider SL, Bruce IN, Thomson W. The pharmacogenetics of methotrexate. Rheumatol, 2007; 46: 1520-4
  15. Kremer JM. Methotrexate pharmacogenomics. Ann Rheum Dis, 2010;22: 112